Bempedoic acid – a new player in the field of hypolipidemic therapy

Česká verzia

Authors: Kristýna Čillíková
Published in the journal: AtheroRev 2024; 9(2): 96-102
Category:

Zdroje

Ray KK, Bays HE, Catapano AL et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med 2019; 380(11): 1022–1032. Dostupn. z DOI: <https://doi: 10.1056/NEJMoa1803917>.

Nicholls SJ, Lincoff AM, Bays HE et el.Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J 2021; 235: 104–112. Dostupné z DOI: https://doi: 10.1016/j.ahj.2020.10.060>.

Nicholls SJ, Nelson AJ, Lincoff AM et el. Impact of Bempedoic Acid on Total Cardiovascular EventsA Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial. JAMA Cardiol 2024; 9(3): 245–253. Dostupné z DOI: https://doi:10.1001/jamacardio.2023.5155>.

Nissen SE, Menon V, Nicholls SJ et al. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA 2023; 330(2):131–140. Dostupné z DOI: https://doi: 10.1001/jama.2023.9696.

Ray KK, Nicholls SJ, ∙ Li N et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol 2024; 12: 19–28. Dostupné z DOI: <https://doi.org/10.1016/S2213–8587(23)00316–9>.

Ballantyne CM, Bays H, Catapano AL et al Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drug Ther 2021; 35(4): 853–864. Dostupné z DOI: <https:// doi.org/ 10.1007/s10557–021–07147–5>.

GoldbergAC, LeiterLA, Stroes ESG et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA 2019; 322(18): 1780–1788. Dostupné z DOI: <https://doi: 10.1001/jama.2019.16585>.

Informace dostupné z WWW: <https://www.clinicaltrials.gov/study/NCT03067441>.

Laufs U, Banach M, Mancini GBJ et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc 2019; 8(7): e011662. Dostupné z DOI: <https://doi: 10.1161/JAHA.118.011662>.

Ballantyne CM, Banach M, Mancini GBJ et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis 2018; 277: 195–203. Dostupné z DOI: <https://doi: 10.1016/j.atherosclerosis.2018.06.002>.

Ballantyne CM, Laufs U, Ray KK et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 2020; 27(6): 593–603. Dostupné z DOI: <https://doi: 10.1177/2047487319864671>.

Ballantyne C, Bays HE, Louie MJ et al. Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid. J Am Heart Assoc 2022; 11:e024531. Dostupné z DOI: <https://doi: 10.1161/JAHA.121.024531>.

Leiter LA, Banach M, Catapano AL et al. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes Obes Metab 2022; 24(5): 868–880. Dostupné z DOI: <https://doi.org/10.1111/dom.14645>.

Gouni-Berthold I, Koskinas K, Averna M et al. Effectiveness and safety of bempedoic acid in routine clinical practice: 1-year follow-up snapshot of the MILOS German cohort. Eur Heart J 2023; 44(2): ehad655.2810. Dostupné z DOI: <https://doi.org/10.1093/eurheartj/ehad655.2810>.

Banach M, Penson PE, Farnier M et al. Bempedoic acid on the management of lipid disorders and cardiovascular risk. 2023 postion paper of the International Lipid Expert Panel (ILEP). Prog Cardiovasc Dis 2023; 79:2–11. Dostupné z DOI: <https://doi: 10.1016/j.pcad.2023.03.001>.